RxDoctor Payments Data

Kevin James, MD

Vascular Surgery · Morristown, NJNPI 1700811353

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (45.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Johnson & Johnson at 45.1% of the total. Reporting peaked in 2021 at $1,989 and has fallen 89.0% since, to $218 in 2025. That places this record below the midpoint for vascular surgery clinicians in NJ, where the typical reported total is $5,209.

$3,894in general payments, 2019–2025

Across 21 payments — averaging $185.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Silk Road Medical, Inc.$1K
  • W. L. Gore & Associates, Inc.$559
  • Medtronic$204
  • Shockwave Medical, Inc$194
  • Cook Medical LLC$98
  • plus $72 from 3 others

What the payments were for

  • Consulting fees$1,75545%
  • Travel & lodging$87522%
  • Food & beverage$1,26432%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,894 in reported general payments places this provider in the 45th percentile of 182 vascular surgery providers in New Jersey.

See all vascular surgery providers in New Jersey →

Medicare billing

Part B allowed, 2024
$294,832
Medicare patients
1,073
Services billed
1,959

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$50,715
XareltoRivaroxaban21$23,330
Cilostazol30$848
ClopidogrelClopidogrel Bisulfate40$402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,755$23,33021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 182 vascular surgery providers in New Jersey.

Other vascular surgery in Morristown

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →